This Week in GLP-1s / May 3-9, 2026
Medicare to cover Wegovy at $50 a month for eligible patients starting July 2026
Lead item
Medicare to cover Wegovy at $50 a month for eligible patients starting July 2026
The Centers for Medicare & Medicaid Services announced that eligible Medicare beneficiaries living with obesity will be able to access Wegovy (semaglutide), available as both an injection and a pill, for a $50 monthly copay beginning July 1, 2026. The program, called the Medicare GLP-1 Bridge, was announced May 6, 2026, and applies to patients who qualify under Medicare's coverage criteria. The announcement came from Novo Nordisk, the manufacturer of Wegovy, in a press release distributed through BioSpace.
The development matters because Medicare has historically excluded weight-loss drugs from coverage, leaving many older Americans to pay out of pocket for medications that can cost over $1,000 a month at list price. Wegovy holds an FDA approval not just for weight management but also for reducing the risk of heart attack, stroke, and cardiovascular death in adults with obesity who also have established heart disease, a distinction Novo Nordisk highlights as unique to its drug. That cardiovascular indication has been a key factor in policy discussions about whether GLP-1 medications should be treated as heart drugs, not just weight-loss drugs, for coverage purposes.
Readers should watch for details on exactly which Medicare beneficiaries qualify, since eligibility criteria have not been fully spelled out in publicly available materials yet. This announcement originated with the drug's manufacturer, and independent confirmation of program terms from CMS directly will be important as the July launch approaches. Patients currently on Medicare who are interested should speak with their prescriber or pharmacist once official program details are published.
Coverage & Access
PrecisionLife and Ovation Target GLP-1 Response Variability with New Biomarker-Driven Collaboration | BioPharm International
PrecisionLife and Ovation.io have partnered to develop predictive biomarker tools for GLP-1 receptor agonist response. Early analyses found that blood sugar control and weight loss are driven by different biological mechanisms, with neuroplasticity and addiction-related pathways also playing a role in treatment response. The companies plan to validate these findings and develop consumer DNA tests and clinical diagno…
What this means for patients
A new research collaboration aims to create genetic tests that predict how well someone will respond to GLP-1 medications, finding that blood sugar control and weight loss may inv…
Oral GLP-1 Pipeline Signals Potential Cost Declines: Eric Levin | AJMC
New oral GLP-1 medications are entering the market and could eventually put downward pressure on prices as additional competitors launch over the next 18 months. Policy discussions around expanded Medicare and Medicaid coverage may also drive costs lower through government-negotiated purchasing, though current oral GLP-1 pricing remains comparable to injectable versions. Over the long term, patient preference for pi…
What this means for patients
New GLP-1 pills in development could make these popular medications more affordable as more competitors enter the market and insurance coverage potentially expands.
‘No change’ for CagriSema as Novo ditches single-chamber device
Novo Nordisk has scrapped development of a co-formulation version of CagriSema that would have used a single-chamber delivery device, but the company says its launch plans are unchanged. CagriSema, a fixed-dose combination of semaglutide and cagrilintide submitted to the FDA, will instead be delivered via a dual-chamber pen. Novo expects U.S. approval in the fourth quarter of this year and a launch in early 2027, wi…
What this means for patients
Novo Nordisk is still on track to launch its next obesity drug, CagriSema, using a two-chamber pen after dropping work on a single-chamber version.
As GLP-1 Use Expands, Long-Term Safety Questions Remain Under Watch | Pharmacy Times
A reported case of liver failure in a patient taking orforglipron, a newly approved oral GLP-1 receptor agonist, has drawn attention to long-term safety monitoring of this drug class. Eli Lilly and multiple analysts note that the isolated FAERS report does not establish a causal link, citing clinical trial data from roughly 11,000 patients showing hepatic safety comparable to placebo. Ongoing surveillance covers bro…
What this means for patients
A single liver failure report in a patient taking the new oral weight-loss drug orforglipron has raised safety questions, but experts say one case doesn't prove the drug was the c…
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial - The Lancet
A randomised, double-blind, placebo-controlled trial published in The Lancet investigated once-weekly semaglutide compared with placebo in patients diagnosed with alcohol use disorder who also had comorbid obesity. The study aimed to evaluate whether semaglutide, a GLP-1 receptor agonist already used for obesity and type 2 diabetes, could reduce alcohol use disorder symptoms in this patient population.
What this means for patients
A new Lancet study tested whether weekly semaglutide helps people with both alcohol use disorder and obesity, compared with a placebo.
Combination & Oral Semaglutide Trial Updates
Regeneron tests new drug combo with Wegovy for obesity
A Phase 2 trial sponsored by Regeneron Pharmaceuticals is evaluating whether adding experimental drugs trevogrumab and garetosmab to semaglutide (Wegovy) is safe and effective for weight loss, fat loss, and lean mass preservation in adults with obesity. The COURAGE trial is no longer enrolling new participants but remains active, with primary completion estimated for May 2026. No results have been published yet, and as an industry-sponsored study, findings should be interpreted with that context in mind.
What this means for patients
Researchers are studying whether two new experimental drugs, when combined with Wegovy, can help people with obesity lose weight while preserving muscle. No results are available yet, so it is too early to know whether this combination is safe or helpful.
Novo Nordisk completes high-dose oral semaglutide trial
A completed Phase 3 trial sponsored by Novo Nordisk evaluated how well a high daily dose of oral semaglutide (50 mg) helped people with overweight or obesity lose weight, compared to a lower dose and a placebo. The study, called STEP UP, finished in late 2024 and results were posted to ClinicalTrials.gov in April 2026. As an industry-sponsored trial, the findings should be considered alongside that sponsorship context.
What this means for patients
This study tested whether a high-dose daily pill version of semaglutide could help people with excess weight lose weight, compared to a lower dose and a sugar-pill group. The trial has finished and results are now publicly available, though the specific amount of weight loss is not included in the current summary.
Distribution & Market Access
Amazon Pharmacy to offer home delivery for oral Ozempic
Amazon Pharmacy announced it will offer home delivery for Novo Nordisk's oral Ozempic (semaglutide), with same-day delivery available in nearly 3,000 cities and towns. According to Fierce Healthcare, customers with a prescription can order through Amazon Pharmacy or pick up at kiosks, even without a Prime membership. The company plans to expand same-day delivery to 4,500 locations by year's end.
Side-Effect Reporting & Real-World Journeys
Survey finds 4.3% of GLP-1 users report injection site reactions
A Reddit post on r/GLP1ResearchTalk cites a Therapeutic Research Center survey of over 2,100 GLP-1 users finding that 4.3% reported injection site reactions like redness or itching, while only 0.8% had systemic allergic reactions. The poster notes these reactions are usually mild and that clinical trials generally show related antibodies do not reduce how well the treatment worked. This reflects a single patient's experience alongside a self-reported survey, not a peer-reviewed study.
What this means for patients
A survey of more than 2,100 GLP-1 users found that 4.3% experienced injection site reactions such as redness or itching, and fewer than 1% had systemic allergic reactions. These reactions are generally mild, and the data come from a self-reported survey shared on Reddit, not a peer-reviewed study.
Zepbound user loses 139 pounds but worries about sustaining habits
A Reddit user on r/Zepbound shared that they lost 139 pounds over 10 months on the medication through a strict diet and exercise routine, but expressed concern about maintaining these habits if they eventually stop the drug. The user noted that food noise is beginning to creep back slightly and worried about the long-term financial cost of staying on Zepbound. This is a single patient's anecdotal experience and does not represent typical outcomes.
What this means for patients
One person on Reddit described losing 139 pounds over 10 months on Zepbound while following a strict diet and exercise plan, but said they are worried about keeping those habits up if they ever come off the drug. They also mentioned concern about the long-term cost. This is one person's experience and does not represent typical outcomes.